These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
592 related articles for article (PubMed ID: 33525396)
1. An Update on Self-Amplifying mRNA Vaccine Development. Blakney AK; Ip S; Geall AJ Vaccines (Basel); 2021 Jan; 9(2):. PubMed ID: 33525396 [TBL] [Abstract][Full Text] [Related]
2. Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines. Blakney AK; McKay PF; Hu K; Samnuan K; Jain N; Brown A; Thomas A; Rogers P; Polra K; Sallah H; Yeow J; Zhu Y; Stevens MM; Geall A; Shattock RJ J Control Release; 2021 Oct; 338():201-210. PubMed ID: 34418521 [TBL] [Abstract][Full Text] [Related]
3. Production, Characterization, and Assessment of Permanently Cationic and Ionizable Lipid Nanoparticles for Use in the Delivery of Self-Amplifying RNA Vaccines. Kairuz D; Samudh N; Ely A; Arbuthnot P; Bloom K Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111658 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of a self-amplifying mRNA reporter vaccine in explant models of broiler chickens. Snoeck J; Chiers K; Tam Y; Sanders NN; Garmyn A Poult Sci; 2023 Nov; 102(11):103078. PubMed ID: 37801866 [TBL] [Abstract][Full Text] [Related]
5. Current Status and Future Perspectives on MRNA Drug Manufacturing. Webb C; Ip S; Bathula NV; Popova P; Soriano SKV; Ly HH; Eryilmaz B; Nguyen Huu VA; Broadhead R; Rabel M; Villamagna I; Abraham S; Raeesi V; Thomas A; Clarke S; Ramsay EC; Perrie Y; Blakney AK Mol Pharm; 2022 Apr; 19(4):1047-1058. PubMed ID: 35238565 [TBL] [Abstract][Full Text] [Related]
6. Polyplex nanomicelle delivery of self-amplifying RNA vaccine. Chang YH; Lin MW; Chien MC; Ke GM; Wu IE; Lin RL; Lin CY; Hu YC J Control Release; 2021 Oct; 338():694-704. PubMed ID: 34509585 [TBL] [Abstract][Full Text] [Related]
7. The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency. Anderluzzi G; Lou G; Woods S; Schmidt ST; Gallorini S; Brazzoli M; Johnson R; Roberts CW; O'Hagan DT; Baudner BC; Perrie Y J Control Release; 2022 Feb; 342():388-399. PubMed ID: 34896446 [TBL] [Abstract][Full Text] [Related]
8. Optimization of Lipid Nanoparticles for saRNA Expression and Cellular Activation Using a Design-of-Experiment Approach. Ly HH; Daniel S; Soriano SKV; Kis Z; Blakney AK Mol Pharm; 2022 Jun; 19(6):1892-1905. PubMed ID: 35604765 [TBL] [Abstract][Full Text] [Related]
9. Vaccines' New Era-RNA Vaccine. Zhou W; Jiang L; Liao S; Wu F; Yang G; Hou L; Liu L; Pan X; Jia W; Zhang Y Viruses; 2023 Aug; 15(8):. PubMed ID: 37632102 [TBL] [Abstract][Full Text] [Related]
10. Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA. Blakney AK; McKay PF; Yus BI; Aldon Y; Shattock RJ Gene Ther; 2019 Sep; 26(9):363-372. PubMed ID: 31300730 [TBL] [Abstract][Full Text] [Related]
11. A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity. Beissert T; Perkovic M; Vogel A; Erbar S; Walzer KC; Hempel T; Brill S; Haefner E; Becker R; Türeci Ö; Sahin U Mol Ther; 2020 Jan; 28(1):119-128. PubMed ID: 31624015 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. Pollock KM; Cheeseman HM; Szubert AJ; Libri V; Boffito M; Owen D; Bern H; O'Hara J; McFarlane LR; Lemm NM; McKay PF; Rampling T; Yim YTN; Milinkovic A; Kingsley C; Cole T; Fagerbrink S; Aban M; Tanaka M; Mehdipour S; Robbins A; Budd W; Faust SN; Hassanin H; Cosgrove CA; Winston A; Fidler S; Dunn DT; McCormack S; Shattock RJ; EClinicalMedicine; 2022 Feb; 44():101262. PubMed ID: 35043093 [TBL] [Abstract][Full Text] [Related]
14. Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses. Liu Y; Li Y; Hu Q Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514957 [TBL] [Abstract][Full Text] [Related]
15. Complete substitution with modified nucleotides suppresses the early interferon response and increases the potency of self-amplifying RNA. McGee JE; Kirsch JR; Kenney D; Chavez E; Shih TY; Douam F; Wong WW; Grinstaff MW bioRxiv; 2023 Sep; ():. PubMed ID: 37745375 [TBL] [Abstract][Full Text] [Related]
16. Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccines. Tregoning JS; Stirling DC; Wang Z; Flight KE; Brown JC; Blakney AK; McKay PF; Cunliffe RF; Murugaiah V; Fox CB; Beattie M; Tam YK; Johansson C; Shattock RJ Mol Ther Nucleic Acids; 2023 Mar; 31():29-42. PubMed ID: 36589712 [TBL] [Abstract][Full Text] [Related]
17. Big Is Beautiful: Enhanced saRNA Delivery and Immunogenicity by a Higher Molecular Weight, Bioreducible, Cationic Polymer. Blakney AK; Zhu Y; McKay PF; Bouton CR; Yeow J; Tang J; Hu K; Samnuan K; Grigsby CL; Shattock RJ; Stevens MM ACS Nano; 2020 May; 14(5):5711-5727. PubMed ID: 32267667 [TBL] [Abstract][Full Text] [Related]
18. Vaccines on demand, part II: future reality. Geall AJ; Kis Z; Ulmer JB Expert Opin Drug Discov; 2023 Feb; 18(2):119-127. PubMed ID: 36384351 [TBL] [Abstract][Full Text] [Related]